Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. has significantly enhanced its manufacturing capabilities by partnering with Charles River for cGMP manufacturing, enabling efficient scaling and compliance with regulatory standards, which positions the company favorably ahead of its anticipated clinical trial launch. The recent closure of a $5 million tranche of a larger financing agreement has strengthened FibroBiologics' financial foundation, providing necessary resources to advance its clinical programs, including the promising first-in-human trial outcomes for diabetic foot ulcers. Additionally, the establishment of a robust cell bank and plans for expanding research facilities underline the company’s commitment to supporting large-scale production of fibroblast-based therapies, thereby reinforcing its strategic leadership in regenerative medicine across multiple therapeutic areas.

Bears say

FibroBiologics Inc faces challenges in its financial outlook due to the high costs associated with the development and commercialization of its fibroblast-based therapies, which may not yield immediate revenue due to their clinical-stage status. Furthermore, the competitive landscape within the cell therapy sector and the complexities surrounding regulatory approvals could constrain the company's ability to secure funding and achieve timely market entry. Lastly, the reliance on targeting specific chronic diseases with limited treatment options raises concerns about the scalability and market viability of FibroBiologics’s product pipeline amid the ever-evolving healthcare environment.

Fibrobiologics Inc (FBLG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.